PMID- 34751777
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220531
IS  - 1530-8561 (Electronic)
IS  - 0009-9147 (Linking)
VI  - 67
IP  - 12
DP  - 2021 Nov 26
TI  - LIPCAR Is Increased in Chronic Symptomatic HF Patients. A Sub-Study of the 
      GISSI-HF Trial.
PG  - 1721-1731
LID - 10.1093/clinchem/hvab197 [doi]
AB  - BACKGROUND: The long noncoding RNA LIPCAR (Long Intergenic noncoding RNA 
      Predicting CARdiac remodeling) has emerged as a promising biomarker in cardiac 
      disease and cardiac remodeling. To determine whether LIPCAR levels help for a 
      molecular phenotyping of chronic heart failure (HF) patients, this study assessed 
      the association of LIPCAR with severity of the disease and its progression, and 
      with risk of death or hospitalization in HF patients. METHODS: LIPCAR was 
      measured in plasma of 967 HF patients with symptomatic heart failure 
      participating in the Gruppo Italiano per lo Studio della Sopravvivenza 
      nell'Insufficienza Cardiaca - Heart Failure (GISSI-HF) biohumoral sub-study. 
      RESULTS: Plasma levels of LIPCAR were significantly associated with functional 
      impairment as assessed by the New York Heart Association (NYHA) class, kidney 
      function as reflected by estimated glomerular filtration rate, and creatinine, 
      hemoglobin and mitral insufficiency. In females, these associations were more 
      marked as compared to males. LIPCAR plasma levels were significantly related to 
      the two cardiac markers, N-terminal pro-B type natriuretic peptide and 
      high-sensitivity cardiac troponin T, but not to inflammatory markers such as high 
      sensitivity C-reactive protein and pentraxin-3, nor to patient reported outcomes 
      such as depression and quality of life. HF patients with high LIPCAR levels 
      univariately showed significantly higher incidence of cardiovascular 
      hospitalizations but not of death; after adjusting for covariates, no significant 
      effects of LIPCAR were found for cardiovascular hospitalizations. CONCLUSION: The 
      circulating long noncoding RNA LIPCAR was increased in HF patients with higher 
      NYHA class, impaired kidney function, and lower hemoglobin, which are indicators 
      of patients' overall state.
CI  - (c) American Association for Clinical Chemistry 2021. All rights reserved. For 
      permissions, please email: journals.permissions@oup.com.
FAU - Meessen, Jennifer M T A
AU  - Meessen JMTA
AD  - Department of Cardiovascular Medicine, Mario Negri Institute for Pharmacological 
      Research IRCCS, Milan, Italy.
FAU - Bar, Christian
AU  - Bar C
AD  - Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical 
      School, Hannover, Germany.
AD  - REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, 
      Hannover, Germany.
FAU - di Dona, Filippo M
AU  - di Dona FM
AD  - Department of Cardiovascular Medicine, Mario Negri Institute for Pharmacological 
      Research IRCCS, Milan, Italy.
FAU - Staszewsky, Lidia I
AU  - Staszewsky LI
AD  - Department of Cardiovascular Medicine, Mario Negri Institute for Pharmacological 
      Research IRCCS, Milan, Italy.
FAU - Di Giulio, Paola
AU  - Di Giulio P
AD  - Department of Public Health and Pediatrics, University of Turin, Turin, Italy.
FAU - Di Tano, Giuseppe
AU  - Di Tano G
AD  - Cardiology Department, ASST of Cremona, Cremona, Italy.
FAU - Costa, Alessia
AU  - Costa A
AD  - Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical 
      School, Hannover, Germany.
AD  - REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, 
      Hannover, Germany.
FAU - Leonardy, Julia
AU  - Leonardy J
AD  - Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical 
      School, Hannover, Germany.
AD  - REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, 
      Hannover, Germany.
FAU - Novelli, Deborah
AU  - Novelli D
AD  - Department of Cardiovascular Medicine, Mario Negri Institute for Pharmacological 
      Research IRCCS, Milan, Italy.
FAU - Nicolis, Enrico B
AU  - Nicolis EB
AD  - Department of Cardiovascular Medicine, Mario Negri Institute for Pharmacological 
      Research IRCCS, Milan, Italy.
FAU - Masson, Serge
AU  - Masson S
AD  - Department of Cardiovascular Medicine, Mario Negri Institute for Pharmacological 
      Research IRCCS, Milan, Italy.
FAU - Pinet, Florence
AU  - Pinet F
AD  - Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - 
      RID-AGE-Facteurs de Risque et Determinants Moleculaires des Maladies Liees au 
      Vieillissement, Lille, France.
FAU - Thum, Thomas
AU  - Thum T
AD  - Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical 
      School, Hannover, Germany.
AD  - REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, 
      Hannover, Germany.
FAU - Latini, Roberto
AU  - Latini R
AD  - Department of Cardiovascular Medicine, Mario Negri Institute for Pharmacological 
      Research IRCCS, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Biomarkers)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Biomarkers
MH  - Chronic Disease
MH  - Female
MH  - *Heart Failure
MH  - Humans
MH  - Male
MH  - Quality of Life
MH  - *RNA, Long Noncoding
MH  - Ventricular Remodeling
OTO - NOTNLM
OT  - *LIPCAR
OT  - *NYHA class
OT  - *biomarker
OT  - *cardiovascular hospitalization
OT  - *eGFR
OT  - *heart failure
OT  - *long noncoding RNA
EDAT- 2021/11/10 06:00
MHDA- 2022/04/14 06:00
CRDT- 2021/11/09 12:23
PHST- 2021/02/10 00:00 [received]
PHST- 2021/08/26 00:00 [accepted]
PHST- 2021/11/10 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
PHST- 2021/11/09 12:23 [entrez]
AID - 6424137 [pii]
AID - 10.1093/clinchem/hvab197 [doi]
PST - ppublish
SO  - Clin Chem. 2021 Nov 26;67(12):1721-1731. doi: 10.1093/clinchem/hvab197.